<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801294</url>
  </required_header>
  <id_info>
    <org_study_id>1239.2</org_study_id>
    <secondary_id>EudraCT 2006-000893-56</secondary_id>
    <nct_id>NCT00801294</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to explore the overall objective best response rate
      and the rate of non-progression at 16 weeks of sequential, alternating weekly administration
      of BIBF 1120 and BIBW 2992 in patients with metastatic CRC based on the RECIST criteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2006</start_date>
  <primary_completion_date type="Actual">November 1, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>The RECIST criterion will be used to assess: objective response rate (PR + CR), and disease progression within the first 16 weeks</measure>
    <time_frame>every 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (based on the RECIST criteria)</measure>
    <time_frame>66 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>66 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and intensity of Adverse Events with grading of Adverse Events according to the US NCI Common Terminology Criteria for Adverse Events (CTCAE version 3.0)</measure>
    <time_frame>66 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in safety laboratory parameters</measure>
    <time_frame>66 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of dose reduction guidelines in managing adverse events</measure>
    <time_frame>66 Weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120 and BIBW 2992</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 18 years.

          2. Signed informed consent.

          3. Histologically proven colorectal adenocarcinoma

          4. History or presence of metastatic colorectal cancer (stage IV)

          5. Measurable (&gt;1 cm) or evaluable tumour deposit (according to RECIST criteria)

          6. Documented progression or unacceptable toxicity on the last therapy

          7. Progression on oxaliplatin-based chemotherapy or unacceptable residual neurotoxicity
             on oxaliplatin

          8. Progression on irinotecan-based chemotherapy or unacceptable toxicity on irinotecan

          9. If patients have been previously exposed to Cetuximab or other EGFR inhibitor, they
             must have shown progression or unacceptable toxicity

         10. If patients have been previously exposed to Bevacizumab or other VEGF inhibitor, they
             must have shown progression or unacceptable toxicity

         11. Life expectancy of at least 12 weeks.

         12. WHO (ECOG) performance status &lt;= 2, &lt;= 1 if age &gt; 75 years.

         13. Adequate hepatic function

         14. Adequate renal function

        Exclusion Criteria:

          1. Prior treatment with small molecule EGFR, HER2 or VEGFR tyrosine kinase inhibitors

          2. Treatment with standard chemotherapy or cetuximab within the last 14 days

          3. Treatment with bevacizumab within the last 28 days

          4. History of other malignancies in the last 5 years, which could affect compliance with
             the protocol or interpretation of results. Patients with adequately treated basal or
             squamous cell skin cancer are generally eligible.

          5. Serious illness or concomitant non-oncological disease such as neurologic,
             psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or
             laboratory abnormality

          6. Significant cardiovascular diseases

          7. History of haemorrhagic or thrombotic event in the past 12 months. Known inherited
             predisposition to bleeds or to thrombosis.

          8. Patient with history or clinical or radiological evidence of CNS disease or brain
             metastases.

          9. Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1239.2.3305A clinique Saint Jean</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3305B Cabinet Médical</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301A Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301B Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301C Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301D Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301E Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301F Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301G Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301H Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301I Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301J Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3301K Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3302A Hôpital Tenon</name>
      <address>
        <city>Paris Cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3302B Hôpital Tenon</name>
      <address>
        <city>Paris Cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3304A Hôpital Robert Debré</name>
      <address>
        <city>Reims Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3304B Hôpital Robert Debré</name>
      <address>
        <city>Reims Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3304C Hôpital Robert Debré</name>
      <address>
        <city>Reims Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3303A Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3303B Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3303C Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3303D Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3303E Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1239.2.3303F Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/21737652</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

